MedTrace Logo

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

NCT06150898 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2025-06-13

No results posted yet for this study

Summary

Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer.

To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug.

Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs

Conditions

Interventions

PROCEDURE

Prospective data and sample collection

Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity, lifestyle questionaire

DRUG

Ketorolac 10 Mg Oral Tablet

Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery

DRUG

Pregabalin 75mg

Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery

DRUG

Omeprazole 20mg Capsule

Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery

Sponsors & Collaborators

  • KU Leuven

    collaborator OTHER

  • Jules Bordet Institute

    lead OTHER

Principal Investigators

  • Christine Desmedt, PhD · KU Leuven

  • Imane Bachir, MD · Jules Bordet Institute

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-12
Primary Completion
2027-04-20
Completion
2027-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06150898 on ClinicalTrials.gov